Business Wire

Valar Labs Announces Validation of First Histology-based Test to Predict Response to BCG in Bladder Cancer

PALO ALTO, Calif.--(BUSINESS WIRE)--Valar Labs, the developer of computational histology AI tests for predicting response to cancer therapies, announced new data today which is being presented on ...
Cure Today

TARA-002 Shows Potential in BCG-Naive NMIBC Treatment

TARA-002 demonstrates high complete response rates in BCG-naïve NMIBC patients, with 72% achieving CR and 50% maintaining it at 12 months. The treatment involves six weekly bladder instillations, ...
Hosted on MSN

Protara’s cell therapy touts BCG-naïve treatment potential in Phase II

Protara’s lead candidate, TARA-002, has demonstrated durable complete response (CR) rates in a single-arm Phase II trial in Bacillus Calmette-Guérin (BCG)-naïve non-muscle invasive bladder cancer ...
ascopubs.org

Germline DNA repair gene (gDRG) variants in BCG un-responsive patients: A potential genetic implication for risk stratification and target therapy.

Clinical and genomic correlates of brain metastases in small cell carcinoma of the bladder. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary Cancers Symposium. This abstract does not ...
Morningstar

ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B End-of-Phase meeting with the U.S. FDA regarding the Company’s supplemental ...